 Daniel Ambruso
Concepts (556)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutrophils | 42 | 2025 | 1118 | 4.560 |
Why?
| | NADPH Oxidases | 24 | 2025 | 120 | 3.290 |
Why?
| | Granulomatous Disease, Chronic | 5 | 2025 | 48 | 2.830 |
Why?
| | Interferon-gamma | 4 | 2025 | 781 | 2.030 |
Why?
| | Transfusion Reaction | 14 | 2014 | 61 | 1.610 |
Why?
| | Blood Preservation | 13 | 2013 | 345 | 1.320 |
Why?
| | Peroxiredoxin VI | 4 | 2016 | 9 | 1.220 |
Why?
| | Granulocyte Colony-Stimulating Factor | 9 | 2020 | 89 | 1.180 |
Why?
| | Superoxides | 16 | 2022 | 199 | 1.010 |
Why?
| | Gene Expression Regulation | 3 | 2025 | 2591 | 0.910 |
Why?
| | Isoantibodies | 6 | 2013 | 57 | 0.760 |
Why?
| | Neutrophil Activation | 4 | 2011 | 84 | 0.750 |
Why?
| | Erythrocyte Transfusion | 4 | 2015 | 226 | 0.740 |
Why?
| | Blood Transfusion | 7 | 2014 | 405 | 0.720 |
Why?
| | Membrane Glycoproteins | 2 | 2015 | 496 | 0.680 |
Why?
| | Neutropenia | 4 | 2020 | 155 | 0.670 |
Why?
| | Leukapheresis | 3 | 2014 | 27 | 0.580 |
Why?
| | NADH, NADPH Oxidoreductases | 8 | 1996 | 25 | 0.570 |
Why?
| | Blood Donors | 5 | 2014 | 143 | 0.560 |
Why?
| | Lysophosphatidylcholines | 5 | 2012 | 23 | 0.490 |
Why?
| | Erythrocytes | 8 | 2013 | 750 | 0.480 |
Why?
| | Respiratory Burst | 4 | 2022 | 19 | 0.470 |
Why?
| | Leukocyte Transfusion | 2 | 2014 | 5 | 0.460 |
Why?
| | Pediatrics | 4 | 2014 | 1121 | 0.460 |
Why?
| | Blood Platelets | 9 | 2013 | 379 | 0.450 |
Why?
| | Phospholipases A2 | 3 | 2016 | 79 | 0.440 |
Why?
| | Plasma Substitutes | 1 | 2014 | 5 | 0.440 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2014 | 9 | 0.430 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1766 | 0.430 |
Why?
| | rac GTP-Binding Proteins | 4 | 2004 | 35 | 0.420 |
Why?
| | Platelet Transfusion | 3 | 2009 | 78 | 0.420 |
Why?
| | Thalassemia | 1 | 2014 | 6 | 0.420 |
Why?
| | Glycogen Storage Disease Type I | 3 | 2010 | 9 | 0.410 |
Why?
| | Blood Grouping and Crossmatching | 2 | 2011 | 17 | 0.400 |
Why?
| | Humans | 105 | 2025 | 144665 | 0.390 |
Why?
| | Fetal Blood | 8 | 2005 | 325 | 0.380 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2013 | 14 | 0.380 |
Why?
| | Sweet Syndrome | 1 | 2012 | 10 | 0.370 |
Why?
| | Up-Regulation | 1 | 2015 | 848 | 0.370 |
Why?
| | Educational Technology | 1 | 2012 | 8 | 0.360 |
Why?
| | Phagocytosis | 6 | 2022 | 296 | 0.360 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 48 | 0.360 |
Why?
| | Chemotaxis, Leukocyte | 6 | 2017 | 113 | 0.350 |
Why?
| | Regenerative Medicine | 1 | 2012 | 48 | 0.350 |
Why?
| | Granulocytes | 5 | 2014 | 81 | 0.350 |
Why?
| | Immunity, Innate | 1 | 2017 | 843 | 0.340 |
Why?
| | Cytosol | 6 | 2005 | 214 | 0.340 |
Why?
| | Cell Membrane | 5 | 2011 | 706 | 0.340 |
Why?
| | Isoantigens | 3 | 2006 | 17 | 0.310 |
Why?
| | Antigens, Human Platelet | 1 | 2009 | 10 | 0.300 |
Why?
| | Riboflavin | 1 | 2009 | 15 | 0.300 |
Why?
| | Teaching | 1 | 2012 | 237 | 0.300 |
Why?
| | Anemia, Sickle Cell | 3 | 2011 | 312 | 0.300 |
Why?
| | Photosensitizing Agents | 1 | 2009 | 41 | 0.290 |
Why?
| | Colitis, Ulcerative | 1 | 2010 | 148 | 0.290 |
Why?
| | Azepines | 6 | 1998 | 106 | 0.280 |
Why?
| | Lipids | 4 | 1998 | 706 | 0.270 |
Why?
| | Cytoplasmic Granules | 4 | 2004 | 76 | 0.270 |
Why?
| | Triazoles | 6 | 1998 | 184 | 0.260 |
Why?
| | Cell Differentiation | 1 | 2015 | 2037 | 0.260 |
Why?
| | Phosphoproteins | 2 | 2002 | 339 | 0.260 |
Why?
| | Lactoferrin | 8 | 2003 | 36 | 0.260 |
Why?
| | Mitogen-Activated Protein Kinases | 4 | 2004 | 287 | 0.260 |
Why?
| | Pharmaceutical Preparations | 1 | 2008 | 170 | 0.250 |
Why?
| | Ultraviolet Rays | 1 | 2009 | 384 | 0.240 |
Why?
| | Tetradecanoylphorbol Acetate | 5 | 2012 | 150 | 0.240 |
Why?
| | Bacterial Infections | 2 | 2005 | 247 | 0.240 |
Why?
| | Platelet Activating Factor | 4 | 1996 | 45 | 0.240 |
Why?
| | Leukocyte Count | 6 | 2022 | 315 | 0.230 |
Why?
| | Lung Diseases | 4 | 2004 | 781 | 0.230 |
Why?
| | Peroxidase | 6 | 2017 | 167 | 0.220 |
Why?
| | Lactoglobulins | 4 | 1990 | 6 | 0.210 |
Why?
| | Pulmonary Circulation | 1 | 2006 | 429 | 0.210 |
Why?
| | NADPH Oxidase 2 | 2 | 2015 | 32 | 0.210 |
Why?
| | Adult | 30 | 2025 | 40486 | 0.210 |
Why?
| | Benzazepines | 1 | 2004 | 35 | 0.210 |
Why?
| | Phospholipases A | 2 | 2002 | 97 | 0.210 |
Why?
| | Blood Bactericidal Activity | 5 | 2010 | 38 | 0.200 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2000 | 66 | 0.200 |
Why?
| | Acute Lung Injury | 3 | 2012 | 301 | 0.200 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2012 | 231 | 0.190 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 245 | 0.190 |
Why?
| | Peroxidases | 1 | 2002 | 29 | 0.180 |
Why?
| | Cell Line | 4 | 2017 | 2821 | 0.180 |
Why?
| | K562 Cells | 2 | 2013 | 93 | 0.180 |
Why?
| | Neopterin | 1 | 2022 | 13 | 0.180 |
Why?
| | HLA Antigens | 5 | 2002 | 235 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.180 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 5 | 2003 | 38 | 0.180 |
Why?
| | Cell-Free System | 3 | 2013 | 53 | 0.170 |
Why?
| | Anemia, Aplastic | 3 | 1990 | 42 | 0.170 |
Why?
| | Blotting, Western | 4 | 2017 | 1161 | 0.170 |
Why?
| | Healthy Volunteers | 1 | 2022 | 215 | 0.170 |
Why?
| | Glucose-6-Phosphatase | 1 | 2020 | 31 | 0.170 |
Why?
| | Soft Tissue Infections | 1 | 2001 | 39 | 0.170 |
Why?
| | Male | 36 | 2025 | 72425 | 0.160 |
Why?
| | Disease Management | 1 | 2025 | 650 | 0.160 |
Why?
| | Platelet Membrane Glycoproteins | 4 | 2003 | 30 | 0.160 |
Why?
| | Burns | 3 | 1996 | 371 | 0.160 |
Why?
| | Transferrin | 3 | 1991 | 50 | 0.160 |
Why?
| | Infant, Newborn | 12 | 2014 | 6399 | 0.160 |
Why?
| | Hematocrit | 1 | 2000 | 108 | 0.160 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 949 | 0.150 |
Why?
| | RNA, Small Interfering | 2 | 2013 | 631 | 0.150 |
Why?
| | Iron | 6 | 1991 | 358 | 0.150 |
Why?
| | Cytochrome b Group | 4 | 2005 | 22 | 0.150 |
Why?
| | Infant | 12 | 2014 | 10022 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 3 | 2014 | 419 | 0.150 |
Why?
| | Copper | 2 | 1990 | 113 | 0.140 |
Why?
| | Muramidase | 2 | 2017 | 66 | 0.140 |
Why?
| | Glutamate-Ammonia Ligase | 2 | 2013 | 9 | 0.140 |
Why?
| | Antioxidants | 1 | 2002 | 546 | 0.140 |
Why?
| | Apoptosis | 4 | 2017 | 2397 | 0.140 |
Why?
| | Child | 16 | 2022 | 22599 | 0.140 |
Why?
| | Transplantation Conditioning | 3 | 2014 | 186 | 0.140 |
Why?
| | Stem Cell Factor | 1 | 1998 | 16 | 0.140 |
Why?
| | Recombinant Proteins | 6 | 2004 | 1363 | 0.130 |
Why?
| | Hydrogen Peroxide | 2 | 2013 | 334 | 0.120 |
Why?
| | NADPH Oxidase 1 | 1 | 2016 | 2 | 0.120 |
Why?
| | Immunoglobulin M | 2 | 2007 | 281 | 0.120 |
Why?
| | Leukocytosis | 2 | 2014 | 32 | 0.120 |
Why?
| | Antibody Specificity | 2 | 2013 | 178 | 0.120 |
Why?
| | Female | 29 | 2025 | 78301 | 0.110 |
Why?
| | Enzyme Activation | 6 | 2004 | 762 | 0.110 |
Why?
| | Down Syndrome | 1 | 2022 | 522 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 751 | 0.110 |
Why?
| | Adolescent | 14 | 2022 | 22405 | 0.110 |
Why?
| | Vitreous Hemorrhage | 1 | 2015 | 10 | 0.110 |
Why?
| | Leukocytes | 2 | 2013 | 294 | 0.110 |
Why?
| | Hemoglobin SC Disease | 1 | 2015 | 14 | 0.110 |
Why?
| | Calcium | 4 | 2003 | 1182 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 90 | 0.110 |
Why?
| | Blood Proteins | 3 | 2013 | 233 | 0.110 |
Why?
| | Oxygen Consumption | 4 | 1990 | 717 | 0.110 |
Why?
| | Young Adult | 3 | 2022 | 14119 | 0.100 |
Why?
| | Kidney Diseases | 2 | 2014 | 427 | 0.100 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 131 | 0.100 |
Why?
| | Thrombophilia | 1 | 2014 | 89 | 0.100 |
Why?
| | Reference Values | 3 | 2022 | 794 | 0.100 |
Why?
| | Retinal Diseases | 1 | 2015 | 101 | 0.100 |
Why?
| | Meta-Analysis as Topic | 1 | 2014 | 170 | 0.100 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2014 | 103 | 0.100 |
Why?
| | Oxidation-Reduction | 4 | 2013 | 1078 | 0.100 |
Why?
| | Phenotype | 1 | 2022 | 3147 | 0.100 |
Why?
| | Wound Healing | 1 | 2016 | 352 | 0.100 |
Why?
| | Drug Hypersensitivity | 1 | 2014 | 89 | 0.100 |
Why?
| | Rho(D) Immune Globulin | 1 | 2013 | 6 | 0.100 |
Why?
| | Coombs Test | 1 | 2013 | 5 | 0.100 |
Why?
| | Time Factors | 6 | 2013 | 7140 | 0.100 |
Why?
| | Interleukin-8 | 2 | 2009 | 269 | 0.100 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2013 | 14 | 0.100 |
Why?
| | Enzyme Assays | 1 | 2013 | 25 | 0.090 |
Why?
| | Bone Marrow Transplantation | 3 | 2000 | 293 | 0.090 |
Why?
| | Cell Movement | 2 | 2016 | 959 | 0.090 |
Why?
| | Colon | 2 | 2016 | 307 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2014 | 172 | 0.090 |
Why?
| | Protein Binding | 7 | 2016 | 2243 | 0.090 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 334 | 0.090 |
Why?
| | Subcellular Fractions | 3 | 2000 | 73 | 0.090 |
Why?
| | Kinetics | 2 | 2013 | 1603 | 0.090 |
Why?
| | Receptors, Cell Surface | 2 | 2003 | 370 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 1995 | 886 | 0.080 |
Why?
| | Tretinoin | 1 | 2012 | 124 | 0.080 |
Why?
| | Transgenes | 1 | 2011 | 191 | 0.080 |
Why?
| | Critical Illness | 2 | 2014 | 888 | 0.080 |
Why?
| | Histocompatibility Testing | 1 | 2011 | 122 | 0.080 |
Why?
| | Protein Subunits | 1 | 2011 | 228 | 0.080 |
Why?
| | Parvoviridae Infections | 1 | 1990 | 12 | 0.080 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 732 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2010 | 184 | 0.080 |
Why?
| | Carbonates | 1 | 1990 | 13 | 0.080 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 1990 | 34 | 0.080 |
Why?
| | Protein Isoforms | 1 | 2011 | 396 | 0.080 |
Why?
| | Health Services Needs and Demand | 1 | 2012 | 276 | 0.080 |
Why?
| | Remission Induction | 1 | 2010 | 309 | 0.080 |
Why?
| | Disease Susceptibility | 2 | 2005 | 342 | 0.080 |
Why?
| | Pathology | 1 | 2009 | 21 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2005 | 3603 | 0.080 |
Why?
| | Middle Aged | 11 | 2022 | 35968 | 0.070 |
Why?
| | Diethylhexyl Phthalate | 1 | 2009 | 13 | 0.070 |
Why?
| | Plasticizers | 1 | 2009 | 18 | 0.070 |
Why?
| | Signal Transduction | 4 | 2017 | 5185 | 0.070 |
Why?
| | Plateletpheresis | 1 | 2009 | 28 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2022 | 17147 | 0.070 |
Why?
| | Vanadates | 1 | 1989 | 17 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1056 | 0.070 |
Why?
| | Bone Marrow | 5 | 2004 | 306 | 0.070 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2004 | 265 | 0.070 |
Why?
| | Child, Preschool | 8 | 2014 | 11789 | 0.070 |
Why?
| | Cell Survival | 2 | 2014 | 1092 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 609 | 0.070 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1569 | 0.070 |
Why?
| | Sepsis | 1 | 2014 | 643 | 0.070 |
Why?
| | Colonoscopy | 1 | 2010 | 260 | 0.070 |
Why?
| | Blood Component Removal | 2 | 2001 | 26 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 628 | 0.070 |
Why?
| | Curriculum | 2 | 2012 | 1063 | 0.070 |
Why?
| | Deferoxamine | 2 | 1989 | 27 | 0.060 |
Why?
| | Students, Medical | 1 | 2012 | 374 | 0.060 |
Why?
| | Oxygen | 4 | 2002 | 984 | 0.060 |
Why?
| | Phosphorylation | 5 | 2016 | 1704 | 0.060 |
Why?
| | Guidelines as Topic | 1 | 2008 | 267 | 0.060 |
Why?
| | Diphosphoglyceric Acids | 1 | 1986 | 3 | 0.060 |
Why?
| | West Nile virus | 1 | 2007 | 41 | 0.060 |
Why?
| | Autoantibodies | 3 | 2009 | 1505 | 0.060 |
Why?
| | West Nile Fever | 1 | 2007 | 57 | 0.060 |
Why?
| | Tyrosine | 2 | 2003 | 219 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2006 | 221 | 0.060 |
Why?
| | Erythroblastosis, Fetal | 1 | 2005 | 5 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2006 | 245 | 0.060 |
Why?
| | Hepatolenticular Degeneration | 1 | 1985 | 15 | 0.060 |
Why?
| | Viremia | 1 | 2007 | 159 | 0.060 |
Why?
| | Antigens, CD | 2 | 2000 | 552 | 0.060 |
Why?
| | Molecular Weight | 2 | 2003 | 312 | 0.060 |
Why?
| | Blood Cell Count | 2 | 2022 | 55 | 0.060 |
Why?
| | Thrombophlebitis | 2 | 1982 | 12 | 0.060 |
Why?
| | Antithrombin III | 2 | 1982 | 18 | 0.060 |
Why?
| | ABO Blood-Group System | 1 | 2005 | 55 | 0.060 |
Why?
| | Hydroxides | 3 | 1985 | 27 | 0.050 |
Why?
| | Antibodies, Viral | 2 | 2007 | 672 | 0.050 |
Why?
| | Blood Transfusion, Autologous | 1 | 2004 | 18 | 0.050 |
Why?
| | Superoxide Dismutase | 2 | 2004 | 303 | 0.050 |
Why?
| | Antibodies, Monoclonal | 3 | 1993 | 1505 | 0.050 |
Why?
| | DNA, Viral | 3 | 2001 | 357 | 0.050 |
Why?
| | Prostatectomy | 1 | 2004 | 94 | 0.050 |
Why?
| | CD11b Antigen | 1 | 2004 | 60 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3523 | 0.050 |
Why?
| | Cytochromes c | 1 | 2004 | 52 | 0.050 |
Why?
| | Blood Banks | 2 | 2002 | 50 | 0.050 |
Why?
| | Endothelial Cells | 2 | 2009 | 864 | 0.050 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2002 | 677 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2004 | 104 | 0.050 |
Why?
| | Cell Fractionation | 2 | 2002 | 49 | 0.050 |
Why?
| | Translocation, Genetic | 1 | 2004 | 118 | 0.050 |
Why?
| | HIV-1 | 2 | 2000 | 897 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 1986 | 501 | 0.050 |
Why?
| | Hypotension | 1 | 2004 | 126 | 0.050 |
Why?
| | Population Surveillance | 1 | 2007 | 484 | 0.050 |
Why?
| | CD11 Antigens | 2 | 2003 | 29 | 0.050 |
Why?
| | Platelet Aggregation | 2 | 1998 | 98 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2005 | 1301 | 0.050 |
Why?
| | Antigens, CD34 | 2 | 2000 | 88 | 0.050 |
Why?
| | Risk Factors | 4 | 2014 | 10796 | 0.050 |
Why?
| | Peroxiredoxins | 1 | 2002 | 26 | 0.050 |
Why?
| | Two-Hybrid System Techniques | 1 | 2002 | 59 | 0.050 |
Why?
| | Graft vs Host Reaction | 1 | 1982 | 2 | 0.050 |
Why?
| | NADP | 2 | 2016 | 53 | 0.050 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1982 | 2 | 0.050 |
Why?
| | Tissue and Organ Harvesting | 1 | 2002 | 78 | 0.040 |
Why?
| | Oxidants | 1 | 2002 | 103 | 0.040 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2002 | 15 | 0.040 |
Why?
| | Biomarkers | 2 | 2014 | 4261 | 0.040 |
Why?
| | Thymus Gland | 1 | 1983 | 311 | 0.040 |
Why?
| | Age Distribution | 1 | 2002 | 402 | 0.040 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2001 | 56 | 0.040 |
Why?
| | Hemofiltration | 1 | 2001 | 24 | 0.040 |
Why?
| | src-Family Kinases | 1 | 2001 | 92 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 1982 | 164 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 601 | 0.040 |
Why?
| | Podophyllotoxin | 1 | 1980 | 8 | 0.040 |
Why?
| | Macrophages | 3 | 2004 | 1496 | 0.040 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2000 | 15 | 0.040 |
Why?
| | Lymphatic Diseases | 1 | 1980 | 21 | 0.040 |
Why?
| | Ascorbic Acid | 1 | 1982 | 171 | 0.040 |
Why?
| | Guanosine Diphosphate | 1 | 2000 | 20 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 2000 | 26 | 0.040 |
Why?
| | Minority Groups | 1 | 2002 | 283 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2001 | 168 | 0.040 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1980 | 7 | 0.040 |
Why?
| | Antithrombin III Deficiency | 1 | 1980 | 8 | 0.040 |
Why?
| | In Vitro Techniques | 4 | 1998 | 1046 | 0.040 |
Why?
| | Platelet Count | 2 | 1993 | 94 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2002 | 259 | 0.040 |
Why?
| | Abnormalities, Multiple | 1 | 2002 | 197 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2000 | 37 | 0.040 |
Why?
| | Acute Disease | 2 | 1998 | 1029 | 0.040 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2000 | 27 | 0.040 |
Why?
| | Phagocytes | 1 | 2000 | 79 | 0.040 |
Why?
| | Etoposide | 1 | 1980 | 168 | 0.040 |
Why?
| | Electron Spin Resonance Spectroscopy | 2 | 1990 | 96 | 0.040 |
Why?
| | Tissue Donors | 1 | 2002 | 413 | 0.040 |
Why?
| | Risk Assessment | 2 | 2014 | 3729 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 1262 | 0.040 |
Why?
| | Animals | 8 | 2014 | 37948 | 0.040 |
Why?
| | Endothelial Growth Factors | 1 | 1998 | 62 | 0.030 |
Why?
| | Mibefradil | 1 | 1998 | 9 | 0.030 |
Why?
| | Lymphokines | 1 | 1998 | 128 | 0.030 |
Why?
| | Liver Transplantation | 1 | 1985 | 826 | 0.030 |
Why?
| | Blood Transfusion, Intrauterine | 1 | 1998 | 1 | 0.030 |
Why?
| | Leukotriene E4 | 1 | 1998 | 24 | 0.030 |
Why?
| | alpha-Thalassemia | 1 | 1998 | 5 | 0.030 |
Why?
| | Tetrahydronaphthalenes | 1 | 1998 | 31 | 0.030 |
Why?
| | Thrombasthenia | 1 | 1997 | 2 | 0.030 |
Why?
| | Mass Spectrometry | 2 | 2013 | 743 | 0.030 |
Why?
| | Chimera | 1 | 1998 | 61 | 0.030 |
Why?
| | Syndrome | 3 | 2005 | 379 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1998 | 105 | 0.030 |
Why?
| | Lymphocytes | 1 | 2000 | 379 | 0.030 |
Why?
| | Prospective Studies | 3 | 2014 | 7994 | 0.030 |
Why?
| | Viral Load | 1 | 2000 | 528 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2004 | 923 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2004 | 978 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 1998 | 165 | 0.030 |
Why?
| | Factor VIII | 1 | 1977 | 105 | 0.030 |
Why?
| | Plasma | 2 | 1998 | 223 | 0.030 |
Why?
| | Antibodies | 2 | 1997 | 396 | 0.030 |
Why?
| | Benzimidazoles | 1 | 1998 | 187 | 0.030 |
Why?
| | Glutathione Peroxidase | 1 | 2016 | 39 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2016 | 78 | 0.030 |
Why?
| | Fetal Diseases | 1 | 1998 | 193 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2136 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1726 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 1996 | 202 | 0.030 |
Why?
| | Epithelium | 1 | 2016 | 310 | 0.030 |
Why?
| | Centrifugation | 1 | 2014 | 28 | 0.030 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 1994 | 24 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2001 | 1154 | 0.030 |
Why?
| | Automation | 1 | 2014 | 104 | 0.030 |
Why?
| | Blood | 1 | 1994 | 106 | 0.030 |
Why?
| | HIV Infections | 2 | 2000 | 3148 | 0.030 |
Why?
| | Oxidoreductases | 1 | 1994 | 95 | 0.030 |
Why?
| | Donor Selection | 1 | 2014 | 79 | 0.030 |
Why?
| | Allografts | 1 | 2014 | 150 | 0.030 |
Why?
| | Acetylation | 1 | 1994 | 249 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 1998 | 496 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2014 | 95 | 0.030 |
Why?
| | Pertussis Toxin | 2 | 2003 | 24 | 0.030 |
Why?
| | Embryonic and Fetal Development | 1 | 1973 | 93 | 0.020 |
Why?
| | Age Factors | 2 | 2014 | 3329 | 0.020 |
Why?
| | HTLV-II Infections | 1 | 1993 | 3 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 1993 | 165 | 0.020 |
Why?
| | HTLV-I Infections | 1 | 1993 | 28 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1993 | 127 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 527 | 0.020 |
Why?
| | Forecasting | 1 | 2014 | 391 | 0.020 |
Why?
| | Free Radicals | 3 | 1986 | 110 | 0.020 |
Why?
| | Living Donors | 1 | 2014 | 281 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1998 | 2521 | 0.020 |
Why?
| | Dexamethasone | 1 | 2014 | 366 | 0.020 |
Why?
| | Delivery, Obstetric | 1 | 1973 | 161 | 0.020 |
Why?
| | Platelet Adhesiveness | 2 | 1997 | 14 | 0.020 |
Why?
| | Oxidative Stress | 2 | 2009 | 1338 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2014 | 605 | 0.020 |
Why?
| | rac1 GTP-Binding Protein | 2 | 2004 | 56 | 0.020 |
Why?
| | Pulmonary Artery | 1 | 1998 | 1124 | 0.020 |
Why?
| | Cell Adhesion | 2 | 2003 | 452 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2004 | 2950 | 0.020 |
Why?
| | Rats | 2 | 1998 | 5570 | 0.020 |
Why?
| | Body Surface Area | 1 | 1991 | 34 | 0.020 |
Why?
| | Blood Pressure | 1 | 1998 | 1766 | 0.020 |
Why?
| | Animals, Newborn | 1 | 1973 | 890 | 0.020 |
Why?
| | Drug Design | 1 | 2012 | 176 | 0.020 |
Why?
| | Microscopy, Fluorescence | 2 | 2004 | 407 | 0.020 |
Why?
| | Awards and Prizes | 1 | 1991 | 72 | 0.020 |
Why?
| | Fourier Analysis | 1 | 1990 | 41 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 835 | 0.020 |
Why?
| | Filgrastim | 2 | 2000 | 13 | 0.020 |
Why?
| | Behavior, Animal | 1 | 1973 | 521 | 0.020 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 1989 | 6 | 0.020 |
Why?
| | Deamino Arginine Vasopressin | 1 | 1989 | 13 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 324 | 0.020 |
Why?
| | Oxalates | 1 | 1989 | 10 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 2 | 2000 | 277 | 0.020 |
Why?
| | Hyponatremia | 1 | 1989 | 43 | 0.020 |
Why?
| | Spin Labels | 1 | 1989 | 59 | 0.020 |
Why?
| | Esters | 1 | 2009 | 72 | 0.020 |
Why?
| | Colony-Stimulating Factors | 1 | 1988 | 37 | 0.020 |
Why?
| | Incidence | 2 | 2007 | 2892 | 0.020 |
Why?
| | General Surgery | 1 | 1991 | 206 | 0.020 |
Why?
| | Macromolecular Substances | 1 | 1989 | 219 | 0.020 |
Why?
| | Milk, Human | 1 | 1990 | 172 | 0.020 |
Why?
| | Aged | 5 | 2007 | 25955 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 427 | 0.020 |
Why?
| | Nitrogen | 1 | 1989 | 170 | 0.020 |
Why?
| | Agranulocytosis | 1 | 1987 | 30 | 0.020 |
Why?
| | Lithium | 1 | 1987 | 40 | 0.020 |
Why?
| | Pregnancy | 4 | 2005 | 7122 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 444 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 1987 | 76 | 0.020 |
Why?
| | Blood Group Antigens | 1 | 1987 | 15 | 0.020 |
Why?
| | Pancytopenia | 1 | 1986 | 7 | 0.020 |
Why?
| | Injections, Subcutaneous | 2 | 1989 | 168 | 0.020 |
Why?
| | 2,3-Diphosphoglycerate | 1 | 1986 | 32 | 0.020 |
Why?
| | Propionates | 1 | 1986 | 38 | 0.020 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 1 | 1986 | 25 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 1987 | 144 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1986 | 106 | 0.010 |
Why?
| | Proteomics | 1 | 2013 | 1183 | 0.010 |
Why?
| | Monocytes | 2 | 1985 | 536 | 0.010 |
Why?
| | Phosphorus | 1 | 1986 | 98 | 0.010 |
Why?
| | RNA, Viral | 2 | 2000 | 689 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 2005 | 19 | 0.010 |
Why?
| | Bleeding Time | 1 | 1985 | 5 | 0.010 |
Why?
| | Blood Platelet Disorders | 1 | 1985 | 10 | 0.010 |
Why?
| | Failure to Thrive | 1 | 1985 | 28 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1985 | 105 | 0.010 |
Why?
| | Pyoderma | 1 | 1985 | 3 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1985 | 70 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 63 | 0.010 |
Why?
| | Exocytosis | 1 | 1984 | 85 | 0.010 |
Why?
| | T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2004 | 4 | 0.010 |
Why?
| | Guanine Nucleotides | 1 | 2004 | 12 | 0.010 |
Why?
| | Cell Surface Extensions | 1 | 2004 | 13 | 0.010 |
Why?
| | Enzyme Induction | 1 | 2004 | 88 | 0.010 |
Why?
| | Hematopoiesis | 2 | 2000 | 193 | 0.010 |
Why?
| | Cell Size | 1 | 2004 | 92 | 0.010 |
Why?
| | COS Cells | 1 | 2004 | 177 | 0.010 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2004 | 63 | 0.010 |
Why?
| | I-kappa B Proteins | 1 | 2003 | 74 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1986 | 625 | 0.010 |
Why?
| | Receptors, Peptide | 1 | 2003 | 18 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2003 | 53 | 0.010 |
Why?
| | Receptors, Formyl Peptide | 1 | 2003 | 17 | 0.010 |
Why?
| | Ferritins | 3 | 1991 | 70 | 0.010 |
Why?
| | Blood Coagulation Disorders | 1 | 1985 | 196 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1983 | 36 | 0.010 |
Why?
| | Immunoelectrophoresis, Two-Dimensional | 1 | 1982 | 4 | 0.010 |
Why?
| | Chromogenic Compounds | 1 | 1982 | 4 | 0.010 |
Why?
| | Thrombin Time | 1 | 1982 | 11 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2004 | 163 | 0.010 |
Why?
| | Chemotaxis | 1 | 2003 | 123 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2004 | 197 | 0.010 |
Why?
| | Volunteers | 1 | 2002 | 39 | 0.010 |
Why?
| | Imidazoles | 1 | 2003 | 246 | 0.010 |
Why?
| | Serine | 1 | 2003 | 142 | 0.010 |
Why?
| | Gestational Age | 2 | 1998 | 980 | 0.010 |
Why?
| | Hemosiderosis | 1 | 1982 | 2 | 0.010 |
Why?
| | Musculoskeletal Abnormalities | 1 | 2002 | 14 | 0.010 |
Why?
| | Inositol Phosphates | 1 | 2001 | 21 | 0.010 |
Why?
| | Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2001 | 15 | 0.010 |
Why?
| | Bone Marrow Diseases | 1 | 2002 | 20 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2001 | 90 | 0.010 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2002 | 24 | 0.010 |
Why?
| | Zinc | 1 | 1985 | 295 | 0.010 |
Why?
| | Surveys and Questionnaires | 2 | 2007 | 6041 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2002 | 55 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 2003 | 206 | 0.010 |
Why?
| | Global Health | 1 | 2005 | 401 | 0.010 |
Why?
| | Chromosome Disorders | 1 | 1982 | 45 | 0.010 |
Why?
| | Lung Injury | 1 | 2004 | 236 | 0.010 |
Why?
| | Actins | 1 | 2004 | 421 | 0.010 |
Why?
| | Cultural Diversity | 1 | 2002 | 85 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 376 | 0.010 |
Why?
| | Thiourea | 1 | 1981 | 41 | 0.010 |
Why?
| | Microtubules | 1 | 2004 | 287 | 0.010 |
Why?
| | Ethylenes | 1 | 1981 | 17 | 0.010 |
Why?
| | Calcium Signaling | 1 | 2003 | 243 | 0.010 |
Why?
| | Mannitol | 1 | 1981 | 40 | 0.010 |
Why?
| | Mutation | 2 | 2004 | 4081 | 0.010 |
Why?
| | Benzoates | 1 | 1981 | 50 | 0.010 |
Why?
| | Catalase | 1 | 1981 | 133 | 0.010 |
Why?
| | Serum Albumin, Bovine | 1 | 1981 | 59 | 0.010 |
Why?
| | Xanthine Oxidase | 1 | 1981 | 79 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 100 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 407 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 431 | 0.010 |
Why?
| | Antigens | 1 | 1982 | 347 | 0.010 |
Why?
| | Guanosine Triphosphate | 1 | 2000 | 89 | 0.010 |
Why?
| | Models, Biological | 2 | 2001 | 1811 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2000 | 156 | 0.010 |
Why?
| | Recurrence | 1 | 1984 | 1136 | 0.010 |
Why?
| | Retroviridae | 1 | 2000 | 101 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 820 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 273 | 0.010 |
Why?
| | NF-kappa B | 1 | 2003 | 657 | 0.010 |
Why?
| | Zymosan | 1 | 1979 | 39 | 0.010 |
Why?
| | Anions | 1 | 1979 | 31 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 1980 | 69 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1980 | 160 | 0.010 |
Why?
| | Blood Glucose | 2 | 1991 | 2326 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2001 | 380 | 0.010 |
Why?
| | Point Mutation | 1 | 2000 | 242 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2000 | 303 | 0.010 |
Why?
| | Luminescent Proteins | 1 | 2000 | 186 | 0.010 |
Why?
| | Hyperlipidemias | 1 | 1980 | 120 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2000 | 409 | 0.010 |
Why?
| | Pyridines | 1 | 2003 | 603 | 0.010 |
Why?
| | Administration, Oral | 1 | 1982 | 851 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 973 | 0.010 |
Why?
| | Cohort Studies | 2 | 2000 | 5957 | 0.010 |
Why?
| | Green Fluorescent Proteins | 1 | 2000 | 407 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1476 | 0.010 |
Why?
| | Megakaryocytes | 1 | 1998 | 34 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 1998 | 78 | 0.010 |
Why?
| | Pedigree | 1 | 1980 | 515 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 1998 | 83 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1998 | 111 | 0.010 |
Why?
| | Seasons | 1 | 2001 | 556 | 0.010 |
Why?
| | Globins | 1 | 1998 | 21 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2001 | 524 | 0.010 |
Why?
| | Integrin alpha2 | 1 | 1997 | 3 | 0.010 |
Why?
| | Integrin beta3 | 1 | 1997 | 14 | 0.010 |
Why?
| | Epinephrine | 1 | 1998 | 154 | 0.010 |
Why?
| | Colony-Forming Units Assay | 2 | 1988 | 95 | 0.010 |
Why?
| | Oxymetholone | 1 | 1977 | 1 | 0.010 |
Why?
| | Proteins | 1 | 2004 | 1016 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 667 | 0.010 |
Why?
| | Thrombin | 1 | 1998 | 167 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 412 | 0.010 |
Why?
| | Vasculitis | 1 | 1977 | 69 | 0.010 |
Why?
| | Platelet Activation | 1 | 1997 | 98 | 0.010 |
Why?
| | Cytoplasm | 1 | 1997 | 257 | 0.010 |
Why?
| | Base Sequence | 1 | 2000 | 2177 | 0.010 |
Why?
| | Autoantigens | 1 | 1980 | 425 | 0.010 |
Why?
| | Liver | 1 | 1985 | 1889 | 0.010 |
Why?
| | Colorado | 1 | 2007 | 4558 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 1998 | 321 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1997 | 564 | 0.010 |
Why?
| | Drug Administration Schedule | 2 | 1989 | 779 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1980 | 1124 | 0.010 |
Why?
| | Collagen | 1 | 1998 | 450 | 0.010 |
Why?
| | United States | 2 | 2004 | 16018 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 1998 | 550 | 0.010 |
Why?
| | Patient Selection | 1 | 2000 | 727 | 0.010 |
Why?
| | Ligands | 1 | 1997 | 662 | 0.010 |
Why?
| | Mice | 2 | 2004 | 18261 | 0.010 |
Why?
| | Protein Conformation | 1 | 1997 | 935 | 0.010 |
Why?
| | Anticoagulants | 1 | 1980 | 729 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2004 | 4539 | 0.010 |
Why?
| | Stomach Ulcer | 1 | 1973 | 12 | 0.010 |
Why?
| | Gravitation | 1 | 1973 | 22 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1977 | 370 | 0.010 |
Why?
| | Immobilization | 1 | 1973 | 53 | 0.010 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1993 | 4 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1997 | 2909 | 0.010 |
Why?
| | Japan | 1 | 1993 | 145 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 1993 | 119 | 0.010 |
Why?
| | Lung | 1 | 2004 | 4089 | 0.010 |
Why?
| | Bicarbonates | 1 | 1991 | 45 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1447 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1977 | 777 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1998 | 2815 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1993 | 1047 | 0.000 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 2 | 0.000 |
Why?
| | Body Weight | 1 | 1973 | 968 | 0.000 |
Why?
| | Learning | 1 | 1973 | 448 | 0.000 |
Why?
| | Administration, Intranasal | 1 | 1989 | 93 | 0.000 |
Why?
| | Hematologic Diseases | 1 | 1989 | 66 | 0.000 |
Why?
| | Infant, Premature | 1 | 1973 | 614 | 0.000 |
Why?
| | Neutralization Tests | 1 | 1988 | 76 | 0.000 |
Why?
| | Prognosis | 1 | 1977 | 4312 | 0.000 |
Why?
| | Emotions | 1 | 1973 | 578 | 0.000 |
Why?
| | Lithium Carbonate | 1 | 1987 | 6 | 0.000 |
Why?
| | Carrier Proteins | 1 | 1991 | 733 | 0.000 |
Why?
| | Treatment Outcome | 1 | 2002 | 11734 | 0.000 |
Why?
| | Drug Overdose | 1 | 1991 | 371 | 0.000 |
Why?
| | Acetylmuramyl-Alanyl-Isoglutamine | 1 | 1985 | 12 | 0.000 |
Why?
| | Gangrene | 1 | 1985 | 11 | 0.000 |
Why?
| | Hydroxyl Radical | 1 | 1985 | 94 | 0.000 |
Why?
| | Patient Compliance | 1 | 1989 | 587 | 0.000 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1989 | 2019 | 0.000 |
Why?
| | Hair | 1 | 1985 | 86 | 0.000 |
Why?
| | Hemorrhage | 1 | 1989 | 813 | 0.000 |
Why?
| | Lipopolysaccharides | 1 | 1985 | 854 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 1993 | 8283 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1977 | 11 | 0.000 |
Why?
|
|
Ambruso's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|